MPM BioImpact Takes Reunion Neuroscience Private
June 1, 2023
Affiliates of biotechnology investor MPM BioImpact agreed to acquire clinical-stage biopharmaceutical company Reunion Neuroscience in an all-cash take-private transaction valued at about US$13.1 million. Reunion shareholders will receive US$1.12 per share in cash; MPM said the acquisition will support advancement of Reunion's lead psychedelic therapeutic RE104 into Phase 2 clinical development.
- Buyers
- MPM BioImpact
- Targets
- Reunion Neuroscience Inc.
- Sellers
- Reunion shareholders
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.